Chairman and CEO address to AGM
Filed with ASX · · 14 pages · English
Earlier from Acrux
- Remaining balance of R&D Tax Incentive Rebate received
- Appendix 4E and FY22 Annual Report
- Acruxs sixth generic dossier accepted by FDA for review
- Acrux announces commercial agreement with Padagis
- Successful patent litigation outcome
Later from Acrux
- Mutual Termination of Co-Development Agreement
- Launch of prilocaine and lidocaine cream in United States
- Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
- Quarterly Activities / Appendix 4C Cashflow Report
- Appendix 4D and Half Year Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux